Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie Gourley

Showing results (81-90 of 145) with videos related to

Pageof 15
Sort By:
The Lancet. Oncology|October 18, 2015
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trialR Paul Symonds, Charlie Gourley, Susan Davidson, et al.
The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
The Lancet. Oncology|September 13, 2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trialJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerStan B Kaye, Jan Lubinski, Ursula Matulonis, et al.
Cancers|April 3, 2021
Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer PatientsThomas Bartl, Jasmine Karacs, Caroline Kreuzinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patientsJohn F Smyth, Charlie Gourley, Graeme Walker, et al.
Cancer|June 3, 2019
High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinumRobert L Hollis, Michael Churchman, Caroline O Michie, et al.
Oncotarget|April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancerSaeed Rafii, Charlie Gourley, Rajiv Kumar, et al.
Neoplasia (New York, N.Y.)|February 22, 2018
Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian CancerMandy Stanske, Stephan Wienert, Dan Cacsire Castillo-Tong, et al.
Scientific Reports|May 11, 2023
Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinomaRobert L Hollis, John P Thomson, Juliette van Baal, et al.
Pageof 15

Showing results (81-90 of 145) with videos related to

Sort By:
Pageof 15
The Lancet. Oncology|October 18, 2015
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trialR Paul Symonds, Charlie Gourley, Susan Davidson, et al.
The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
The Lancet. Oncology|September 13, 2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trialJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerStan B Kaye, Jan Lubinski, Ursula Matulonis, et al.
Cancers|April 3, 2021
Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer PatientsThomas Bartl, Jasmine Karacs, Caroline Kreuzinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patientsJohn F Smyth, Charlie Gourley, Graeme Walker, et al.
Cancer|June 3, 2019
High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinumRobert L Hollis, Michael Churchman, Caroline O Michie, et al.
Oncotarget|April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancerSaeed Rafii, Charlie Gourley, Rajiv Kumar, et al.
Neoplasia (New York, N.Y.)|February 22, 2018
Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian CancerMandy Stanske, Stephan Wienert, Dan Cacsire Castillo-Tong, et al.
Scientific Reports|May 11, 2023
Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinomaRobert L Hollis, John P Thomson, Juliette van Baal, et al.
Pageof 15